Stuart A. Arbuckle - 24 Jun 2025 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
Director
Signature
/s/ Stephen Vander Stoep, attorney-in-fact for Stuart A. Arbuckle
Issuer symbol
RYTM
Transactions as of
24 Jun 2025
Net transactions value
$0
Form type
4
Filing time
26 Jun 2025, 16:37:52 UTC
Previous filing
23 Jun 2025
Next filing
02 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Arbuckle Stuart A Director C/O RHYTHM PHARMACEUTICALS, INC., 222 BERKELEY STREET, 12TH FLOOR, BOSTON /s/ Stephen Vander Stoep, attorney-in-fact for Stuart A. Arbuckle 26 Jun 2025 0001557290

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Stock Option (right to buy) Award $0 +7,037 $0.000000 7,037 24 Jun 2025 Common Stock 7,037 $63.66 Direct F1
transaction RYTM Restricted Stock Units Award $0 +4,712 $0.000000 4,712 24 Jun 2025 Common Stock 4,712 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date.
F2 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F3 The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.